The first clinical data of a natural immunomodulator in colorectal cancer. Hepatogastroenterology 47: 393-395. 2000.
Boros L. G, Lee W-N. P, Hidvégi M, Go V. L. W:
The metabolic effects of fermented wheat germ extract with anti-tumor properties in cultured MIA pancreatic adenocarcino-ma cells. Combined Meeting of the International Association of Pancreatology and the American Pancreatic Association. Chicago, Illinois, USA, 1-5 November 2000. . .
Falkay Gy, Blazsó G:
The antiinflammatory effect of Avemar. The Albert Szent-Györgyi Medical and Pharmaceutical Center, University of Szeged scientific meeting. Szeged, 14 November 2000. . .
2000
Telekes A, Hidvégi M:
The effects of Avemar (1) anti-cancer effects in animals and tumor patients. Nőgyógyászati Onkológia 5: 188-189. 2000.
Medium-term results of immunomodulation supplemented with MSC in the surgical treatment of colorectal carci-noma, incl. treatment of metastases. I. Congress of the Hungarian Society for Clinical Oncology. Budapest, 10-11 November 2000. (Abstract). LAM 11(Suppl1): 1. 2001.
Early experiences with supplementary Avemar treatment in patients with head/neck tumors. I. Congress of the Hungarian Society for Clinical Oncology. Budapest, 10-11 November 2000. (Abstract). LAM 11(Suppl1): 1. 2001.
The effect of Avemar on the regeneration of leukocytes, thrombocytes and reticulocytes in mice receiving sublethal radiation or cyclophosphamide. I. Congress of the Hungarian Society for Clinical Oncology. Budapest, 10-11 November 2000. (Abstract) LAM 11(Suppl1): 1. 2001.
The role of Avemar (wheat germ extract) in enchancing the immunstatus of non-tumor patients. Obesitologia Hungarica Suppl 1(2): 1. 2001.
Ehrenfeld M, Blank M, Shoenfeld Y, Hidvegi M:
Avemar (a new benzoquinone-containing natural product) administration interferes with the Th2 response in experimental SLE and promotes amelioration of the disease. Lupus 10: 622-627. 2001.
Jakab F, Balogh Á, Mayer Á, Lapis K, Hoffmann A, Szentpétery Á, Telekes A, Hidvégi M:
Critical analysis of an anticancer supportive product (MSC) in colorectal patients. 11th World Congress of the International Association of Surgeons & Gastroenterologists in cooperation with the European Association of Endoscopic Surgery. Crete, 1-4 November 2001. (Abstract). Hepatogastroenterology Suppl I 48: CL. 2001.
Telekes A, Hidvégi M:
The effects of Avemar (2): immunological effects. Nőgyógyászati Onkológia 6: 40-41. 2001.
The supportive value Avemar during chemotherapy. New results of the AVEMAR Cancer Research Program. Symposium. 24th Congress of the Hungarian Society for Oncology. Budapest, Hungary. 22-24 November 2001. . .
Jakab F:
Avemar on the survival and disease progression in colorectal cancer patients receiving complex oncological treatment. New results of Avemar Research Symposium. 24th Congress of the Hungarian Society for Oncology. Budapest, Hungary. 22-24 November 2001. . .
2001
Telekes A, Hidvégi M:
The effects of Avemar (3): signal transduction and meta-bolism. Nőgyógyászati Onkológia 6: 144-145. 2001.
Fajka-Boja R, Hidvégi M, Shoenfeld Y, Ion G, Demydenko D, Tömösközi-Farkas R, Vizler Cs, Telekes A, Resetár Á, Monostori É:
Fermented wheat germ extract induces apoptosis and downregulation of major histocompatibility complex class I proteins in tumor T and B cell lines. Int J Oncol 20: 563-570. 2002.
Experimental and clinical results with Avemar (a dried extract from fermented wheat germ) in animal cancer models and in cancer patients. Nőgyógyászati Onkológia 7: 180-185. 2002.
Demidov L. V, Manzjuk L. V, Kharkevitch G. Y, Artamonova E. V, Pirogova N. A:
The antimetastatic effect of Avemar in high-risk melanoma patients. 18th UICC International Cancer Congress. Oslo, Norway. 30. June - 5. July 2002. (Abstract) Int J Cancer 100(S13): 408. 2002.
Jakab F, Shoenfeld Y, Balogh Á, Nichelatti M, Hoffmann A, Kahán Zs, Lapis K, Mayer Á, Sápy P, Szentpétery F, Telekes A, Thurzó L, Vágvölgyi A, Hidvégi M:
A medical nutriment has supportive value in the treatment of colorectal cancer. Br J Cancer 89: 465-469. 2003.
Tompa A, Kocsis Zs, Marcsek Z, Jakab M, Szende B, Hidvégi M:
Chemo-prevention with tamoxifen and Avemar by inducing apoptosis on MCF-7 (ER+) breast cancer cells. 2nd Congress of the World Society of Breast Health, Budapest, Hungary 24-28: 24-28. 2003.
The Efficacy of Tamoxifen in Estrogen Receptor-Positive Breast Cancer Cells Is Enhanced by a Medical Nutriment. Cancer Biotherapy & Radiopharmaceuticals 6: 746-753. 2004.
Cytotoxic activities of fermented wheat germ extract (Avemar) on human gastric carcinoma cells by induction of apoptosis. 2005 ASCO Annual Meeting Abstract No: 4254. 2005.
Recommendation of the Hungarian Society for Face, Mandible and Oral Surgery in the indication of supportive therapy with Avemar. Orv Hetil 147(35): 1709-11. 2006.
Saiko P, Ozsvar-Kozma M, Madlener S, Bernhaus A, Lackner A, Grusch M, Horvath Zs, Krupitza G, Jaeger W, Ammer K, Fritzer-Szekeres M, Szekeres T:
Avemar, a nontoxic fermented wheat germ extract, induces apoptosis and inhibits ribonucleotide reductase in human HL-60 promyelocytic leukemia cells. Cancer Letters 250/2: 323-328. 2007.
Changes in the kinase expression panel of K562 human leukemia after Avemar treatment. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 14143. 2007.
Avemar inhibits the growth of mouse and human xenograft mammary carcinomas comparable
to endocrine treatments. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20
Supplement), 2007: 21132. 2007.
Sukkar GS, Cella F, Rovera G, Nichelatti M, Ragni G, Chiavenna G, Giannoni R, Ferrari C.:
A multicentric prospective open trial on the quality of life and oxidative stress in patients affected by advanced head and neck cancer treated with a new benzoquinone-rich product derived from fermented wheat germ (Avemar). Mediterr J Nutr Metab : 37-42. 2008.
Demidov L. V, Manziuk L. V, Kharkevitch G. Y; Pirogova, N. A; Artamonova, E. V :
Adjuvant Fermented Wheat Germ Extract (Avemar?) Nutraceutical Improves Survival of High-Risk Skin Melanoma Patients: A Randomized, Pilot, Phase II Clinical Study with a 7-Year Follow-Up. Cancer Biother Radiopharm Volume 23, Issue 4.: 477-482. 2008.
